Despite Hybio Pharmaceutical's share price surge, its high P/S ratio and declining medium-term revenue could risk shareholders' investments. If the P/S aligns with recent negative growth rates, investors may face disappointment.

The company's balance sheet is not considered strong due to its high debt and liabilities, coupled with a decrease in revenue and a loss before interest and tax. The company is considered risky due to these factors.

Despite Hybio Pharmaceutical's recent poor growth, its high P/S ratio indicates investor optimism for a business turnaround. However, with medium-term revenue decline and expected industry growth of 35%, these prices may not be sustainable. Shareholders may face a tough period unless circumstances improve.

The company's high P/S ratio and decreasing revenues do not match, causing concerns for investors. Unless the recent medium-term conditions improve significantly, investors may find it difficult to perceive the share price as fair value.

Hybio Pharmaceutical's falling revenue and pre-tax losses pose concerns over its debt level, implying potential threat to the company while its shares seem unaffected. It's deemed risky due to these factors.